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We investigated the natural course of adrenal incidentalomas in 115 patients by means of a long-term endocrine and morphological
(CT) follow-up protocol (median 4 year, range 1–7 year). At entry, we observed 61 subclinical hormonal alterations in 43 patients
(mainly concerning the ACTH–cortisol axis), but confirmatory tests always excluded specific endocrine diseases. In all cases
radiologic signs of benignity were present. Mean values of the hormones examined at last follow-up did not differ from those
recorded at entry. However in individual patients several variations were observed. In particular, 57 endocrine alterations found in 43
patients (37.2%) were no longer confirmed at follow-up, while 35 new alterations in 31 patients (26.9%) appeared de novo. Only four
alterations in three patients (2.6%) persisted. Confirmatory tests were always negative for specific endocrine diseases. No variation in
mean mass size was found between values at entry (25.470.9mm) and at follow-up (25.770.9mm), although in 32 patients (27.8%)
mass size actually increased, while in 24 patients (20.8%) it decreased. In no case were the variations in mass dimension associated
with the appearance of radiological criteria of malignancy. Kaplan–Meier curves indicated that the cumulative risk for mass
enlargement (65%) and for developing endocrine abnormalities (57%) over time was progressive up to 80 months and independent
of haemodynamic and humoral basal characteristics. In conclusion, mass enlargement and the presence or occurrence over time of
subclinical endocrine alterations are frequent and not correlated, can appear at any time, are not associated with any basal predictor
and, finally, are not necessarily indicative of malignant transformation or of progression toward overt disease.
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Several algorithms have been proposed for management of
patients with adrenal incidentalomas. The majority, but not all,
recommend a conservative approach, except for masses suspected
for malignancy and/or clearly hyperfunctioning which need
surgical treatment (Jockenhovel et al, 1992; Ambrosi et al, 1997;
Barzon et al, 1998; Barzon and Boscaro, 2000; Brunt and Moley,
2001; Thompson and Young, 2003; Mansmann et al, 2004).
However, the follow-up of these apparently benign and non-
functioning masses is arbitrary, reflecting the clinical experience of
the individual Unit rather than deriving from clinical studies
planned to evaluate this aspect. The main problem is that the
natural course of adrenal incidentalomas has not yet been fully
clarified. Prespecified protocols that have prospectively investi-
gated the evolution of these masses are scanty and those reported
in the literature have given inconsistent results on the basis of
different duration of observation, number of patients studied and
methodological approaches adopted (Jockenhovel et al, 1992;
Terzolo et al, 1998; Barzon and Boscaro, 2000; Siren et al, 2000). In
particular, it is not known if these masses may increase in size and,
above all, whether this is a marker of malignant transformation or
whether malignancy may also occur without size variation. In
addition, the meaning of the subtle endocrine alterations
frequently observed in these patients remains unclear and it is
uncertain whether such abnormalities may transform into overt
hypersecretion leading to classic endocrine diseases.
The present study was planned about 10 years ago in order to
follow-up patients with adrenal incidentalomas after exclusion of
patients with masses showing hormonal hyperfunction and/or a
radiological picture of malignancy. The selected patients have been
managed by morphological and hormonal investigations at regular
intervals for up to 7 years.
PATIENTS AND METHODS
Patients
Patients with adrenal incidentalomas, that is, clinically unapparent
adrenal masses incidentally detected after imaging studies for
unrelated reasons (Mantero et al, 2000; Mansmann et al, 2004),
were carefully selected for this study. Adopting a diagnostic
procedure followed in our Unit, we submitted the patients to a
basal morpho-functional study. Morphological evaluation was
based on CT using a fast scanner and 3-mm scanning interval.
Criteria of benignity were mass size preferably lower than 35mm,
homogeneity, regular margins, well-defined lesion, attenua-
tion values less than 10 Hounsfield Units, with no-to-mild
homogeneous CT enhancement and rapid (10–15min) wash-
out of more than 50% of the initial enhancement after i.v.
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scontrast (Boland et al, 1998; Pena et al, 2000; Caoili et al, 2002).
Hormonal evaluation included plasma ACTH and cortisol
before and after 1mg dexamethasone (DMX) suppression test,
plasma renin activity, aldosterone and potassium, plasma nora-
drenaline and adrenaline, plasma free and total testosterone,
androstenedione, dehydroepiandrosterone and 17hydroxypro-
gesterone. When endocrine abnormalities were found, confirma-
tory tests were always performed, namely 24-h urinary free cortisol
and 2 and 8mg DMX suppression tests for suspected Cushing’s
syndrome, captopril and saline loading tests for suspicion of
primary aldosteronism, glucagon test and 24-h urinary catecho-
lamines and metanephrines for suspected pheochromocytoma and,
finally, ACTH test when 21-b-hydroxylase deficiency was sus-
pected.
Using this diagnostic work-up, patients presenting radiological
features of malignancy and/or hormonal hypersecretion were
excluded from the study and advised to undergo surgery. Thus,
only patients with radiologically benign masses and no adrenal
hormonal excess, except for isolated, combined or qualitative
subclinical hormone abnormalities, were admitted to a follow-up
study after obtaining their written consent. The resulting group
was composed of 115 patients (72 females and 43 males,
mean7s.d. age 56.5711 year, range age 16–80 year) with masses
right-sided in 59 cases, left-sided in 27 cases and bilateral in 29
cases. In total, 39 patients were normotensive (systolic blood
pressure 122.372.0mmHg and diastolic blood pressure
76.971.0mmHg, mean7s.e.) and 76 hypertensive (systolic blood
pressure 156.571.7mmHg and diastolic blood pressure
94.771.0mmHg). Obesity or overweight was present in 43 patients
(body mass index 29.370.5kgm
 2) while normal-weight was
recorded in 72 patients (body mass index 23.270.3kgm
 2). In
total, 14 patients suffered from diabetes while 101 patients were
normoglycaemic.
The experimental design was an endocrine and morphological
follow-up of at least 1 year after diagnosis in which patients were
evaluated yearly for up to 7 years (median 4 year, range 1–7 year)
following the same diagnostic work-up adopted in basal conditions
and described above.
Experimental design
At entry and during each follow-up, all subjects maintained
their usual diet, except for diabetic patients who observed an
adequate diet. Patients taking drugs (antihypertensives or other
drugs) suspended medication for at least 2 weeks prior to the
study. On the test day, all subjects, respecting 24-h urinary
collection, underwent blood sampling for hormone measurements
(between 0800 and 0900) after overnight fasting and in the sitting
position. At 2300 on the same day they assumed (orally) 1mg
DXM and blood samples for cortisol determination were taken
the following day at 0800. All patients then underwent CT scan
with i.v. contrast.
Assays
Hormone determinations were performed in the same laboratories
throughout the years of the study, using kits from the same
companies and, frequently, the same technicians. All hormones
were assayed in duplicate using specific commercial RIA kits,
except for catecholamines (high-performance liquid chromato-
graphy). Intra-assay and interassay CVs of the hormones were,
respectively: noradrenaline 14 and 20%; adrenaline 17 and 22%;
dehydroepiandrosterone-sulphate (Radim, Rome, Italy) 6.8 and
8.1%; 17hydroxyprogesterone (ICN Biomedicals, Costa Mesa, CA,
USA) 9.4 and 11.8%; androstenedione (Sorin, Saluggia, Italy) 7.1
and 10.8%; cortisol (Immunoteck International, Marseille, France)
5.7 and 6.6%; ACTH (Nichols Institute Diagnostics, San Juan
Capistrano, CA, USA) 3.1 and 7.3%; aldosterone (DiaSorin,
Saluggia, Italy) 9.7 and 11.5%; plasma renin activity (DiaSorin,
Saluggia, Italy) 7.6 and 9.1%; free testosterone (Diagnostic Systems
Laboratories, Inc., Webster, TX) 5.0 and 8.3%; total testosterone
(Medical System, Genova, Italy) 6.0 and 7.8%. Intra-assay and
interassay CVs of the urinary hormones were, respectively:
noradrenaline 14 and 20%; adrenaline 17 and 22%; normetanephr-
ine 7.6 and 12.7% and metanephrine (Immuno Biological
Laboratories, Hamburg, Germany) 18.7 and 11.9%.
Hormonal parameters with normal values
Plasma cortisol: 60–300ngml
 1; ACTH: 9–52pgml
 1; aldoster-
one: o20ngdl
 1; aldosterone/plasma renin activity (ngml
 1h
 1)
ratio: o70 (95% upper confidence limit of normal values
obtained from 82 patients with essential hypertension); dehydroe-
piandrosterone-sulphate: 0.3–4.3mgml
 1; 17hydroxyprogesterone:
0.15–3.4ngml
 1; free testosterone: o3.6pgml
 1 for females
and 10–40pgml
 1 for males; total testosterone: 0.1–1.0ngml
 1
for females and 3.0–10ngml
 1 for males; androstenedione:
0.2–3.1ngml
 1; noradrenaline: o600pgml
 1 and adrenaline:
o80pgml
 1.
Urinary normetanephrine: 30–440mg/24h; metanephrine: 20–
345mg/24h; noradrenaline o80mg/24h; adrenaline o20mg/24h;
and dopamine o400mg/24h.
Normal responses to captopril (50mg os) and saline loading (2l
of saline in 4h) tests: aldosterone values under 15 and 5ngdl
 1,
respectively; normal response to glucagon (1mg i.v.): plasma
noradrenaline plus adrenaline o1000pgml
 1; normal response to
DXM: plasma cortisol o50ngml
 1; normal response to ACTH
(250mg i.v.): plasma 17hydroxyprogesterone o5ngml
 1.
Radiological parameters with benign/malignant criteria
All CT scans were blinded and independently reviewed by two
experienced radiologists using standardized criteria, commonly
used for adrenal gland investigations (Lee et al, 1991; McNicholas
et al, 1995; Korobkin et al, 1996; Szolar and Kammerhuber, 1997;
Cirillo et al, 1998; Pena et al, 2000; Caoili et al, 2002; Kebapci et al,
2003). If discordant opinions were recorded, an additional
evaluation was carried out by a third operator. The diagnosis of
a benign lesion was established when the mass, well-defined,
showed regular margins and homogeneity, and when attenuation
values were less than 10 HU with no-to-mild homogeneous CT
enhancement, and with rapid (10–15min) wash-out of more than
50% of the initial enhancement after i.v. contrast. Other criteria of
benignity, although not essential, were lack of necrosis, absence of
haemorrhage or calcification and size (maximum length and
maximum width) o40mm. In the case of bilateral masses, only
values of the larger mass were reported.
Statistics
Results are given as mean7s.e. Correlations were examined by
linear regression analysis. Comparisons between variables were
tested with Pearson’s w
2 and Student’s t-test, as appropriate.
Survival analysis was used to estimate the likelihood of developing
adrenal hyperfunction, tumor enlargement or tumor reduction.
Kaplan–Meier curves were generated for estimating cumulative
risk of developing adrenal hyperfunction or tumor variation. To
evaluate factors predictive of progressive disease, we selected and
dichotomized the following parameters: sex (females vs males),
obesity (BMI cutoff, 27kgm
 2), arterial hypertension (blood
pressure values cutoff: 140/90mmHg), diabetes (glycaemia value
cutoff: 126mgdl
 1), side (monolateral vs bilateral, left vs right),
endocrine abnormalities (presence or absence) and, finally, mass
size (stratified in three groups: o20mm, 20–35mm, 435mm).
Data were analysed using SPSS/PCþ11.5 statistical software.
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Hormonal picture at entry
In 62.6% of cases (72 out of 115) the endocrine pattern was
normal, while in 37.4% of cases (43 out of 115) we found isolated
or combined, though subclinical, endocrine alterations (Figure 1).
The most frequent abnormality concerned the ACTH–cortisol axis
with 28 alterations in 23 patients (n¼6 low ACTH, n¼1 high
cortisol, n¼7 no DXM suppression, n¼5 low DHEA-S, n¼1 high
cortisol, no DXM suppression and low DHEA-S, n¼1 high cortisol
and no DXM suppression, n¼2 no DXM suppression and low
DHEA-S), followed by the renin–angiotensin system with 18
alterations in 15 patients (PRA suppressed in 15 patients
associated with high aldosterone in three cases: all 15 were
normokaliemic and 12 were hypertensive). Catecholamines pre-
sented alterations in nine patients who showed high noradrenaline
levels and normal adrenaline (all nine were asymptomatic and
eight had stable hypertension). Finally, we observed six alterations
in androgen levels in five females (n¼1 high testosterone, n¼1
high androstenedione, n¼1 both elevated, n¼2 high 17hydro-
xyprogesterone) without evident clinical signs of hyperandrogen-
ism. In summary, we observed 61 endocrine alterations in 43
patients, but in all cases confirmatory tests excluded specific
endocrine diseases.
Radiological picture at entry
Mean maximum mass diameter was 25.470.9mm. In 86% of cases
(99 out of 115), adrenal masses were lower than 35mm on CT,
while in the remaining 16 (14%) mass dimensions were greater.
However, in all cases radiological signs of benignity were present.
Correlations at entry
No correlation was found either between mass dimensions and
endocrine alterations or haemodynamic/metabolic parameters, or
between endocrine alterations and haemodynamic/metabolic
parameters.
Hormonal picture at last follow-up
Mean values of the hormonal parameters examined at the last
follow-up did not significantly differ from those observed at entry
(Table 1). However several endocrine modifications during follow-
up were observed in the individual patients. Thus, 57 endocrine
alterations found in 43 patients (37.2%) were no longer confirmed
at follow-up, while four alterations in three patients (2.6%)
persisted. In contrast, 35 new alterations in 31 patients (26.9%)
appeared de novo. As observed in basal conditions, in these cases
the hormonal abnormalities likewise concerned the ACTH–
cortisol axis and, less frequently, the other hormones (Table 2).
However, in patients in whom the endocrine alterations were
confirmed or appeared de novo at follow-up, confirmatory tests
were always negative for specific endocrine diseases.
Radiological picture at last follow-up
On average, no variation in mass size was found between values at
entry (25.470.9mm) and at follow-up (25.770.9mm). However,
individual evaluation indicated that mass size increased in 32
patients (27.8%) and decreased in 24 (20.8%). These variations were,
Table 1 Hormonal parameters of our patients at entry and at last
follow-up
Parameter
Basal
(n¼115)
Follow-up
(n¼115) Po
Plasma cortisol (ngml
 1) 163.775.2 161.075.4 NS
Plasma cortisolo after DXM (ngml
 1) 25.572.7 21.671.6 NS
ACTH (pgml
 1) 16.272.0 18.074.1 NS
DHEA-S (mgml
 1) 0.7370.05 0.7570.06 NS
Androstenedione (ngml
 1) 1.4370.08 1.4170.08 NS
Total testosterone (ngml
 1) 1.6070.2 1.4970.2 NS
Free testosterone (pgml
 1) 3.9570.9 4.570.7 NS
17hydroxyprogesterone (ngml
 1) 0.9070.06 0.8570.06 NS
Plasma noradrenaline (pgml
 1) 375.4715.8 391.9714.6 NS
Plasma adrenaline (pgml
 1) 36.772.1 32.371.9 NS
Plasma Renin Activity (ngml
 1h
 1) 1.1370.11 1.2370.11 NS
Aldosterone (ngdl
 1) 25.471.6 23.571.0 NS
Plasma potassium (mEql
 1) 4.070.03 4.070.03 NS
The results are expressed as mean7s.e. NS¼not significance.
Table 2 Altered endocrine picture at entry and/or at follow-up
Not confirmed Confirmed De-novo appeared
Endocrine alterations Alterations no. Patients no. Alterations no. Patients no. Alterations no. Patients no.
ACTH–cortisol axis 28 23 4
a 31 8
b 17
Renin–angiotensin system 18 15 0 0 8
c 5
Catecholamines 9 9 0 0 6 6
Androgens/17OH-progesterone 6 5 0 0 3
d 3
aNo suppression of DXM (two cases) and low DHEA-S levels (two cases).
bNo suppression of DXM (three cases), low DHEA-S levels (10 cases), low ACTH levels (four cases),
high cortisol levels (one case).
cLow PRA levels (five cases) and high aldosterone levels (three cases).
dHigh androstenedione levels (one case) and high 17hydroxyprogesterone
levels (two cases). The number of patients in whom hormonal alterations were not confirmed at follow-up (n¼52) does not correspond to the number reported in the
‘Hormonal picture at last follow-up’ section (n¼43), since some patients showed coexistence of more than one hormonal alteration.
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Figure 1 Patient distribution on the basis of endocrine alterations.
ACTH/Cort¼ACTH/cortisol, RAS¼renin–angiotensin system, CAT¼
catecholamines, ANDR¼androstenedione and 17OHPG¼17hydroxy-
progesterone.
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showever, modest because in the former group the increase was
p5mm in 2/3 of cases (21 out of 32 patients), while in the latter
group the decrease was X5mm in only four cases. An increment
greater than 10mm was found in four cases occurring in the first 2
years without further increase at follow-up. A mass reduction greater
than 10mm was found in only two cases, probably due to
spontaneous infarction and subsequent tumor involution.
Careful evaluation indicated that in no case was the variation in
mass dimension associated with the appearance of radiological
criteria of malignancy.
Survival analysis
Kaplan–Meier curves were used to estimate cumulative risk of
developing mass variations over time. The risk of mass enlarge-
ment was globally elevated (65%) and progressive up to 80 months
but similar to that for mass reduction over time (Figure 2). The
risk for mass enlargement was independent of lesion side, sex and
basal endocrine pattern (presence or absence of hormonal
alterations), blood pressure, BMI, glycaemic pattern and mass
size at entry.
The estimated cumulative risk of developing endocrine
abnormalities over time was globally 57% and progressive up to
80 months (Figure 3). The occurrence of endocrine abnormalities
was not significantly associated with lesion side, sex and
body weight, glycaemic control, blood pressure status and
mass size at entry.
To date, all patients are alive except nine who died for accidental
causes (n¼2), stroke (n¼2) or cardiovascular diseases (n¼5). In
addition, seven patients rejected further tests after the first follow-
up (1 year) and 36 patients dropped out after 4 yearly
observations. Seven patients developed hypertension and four
diabetes during follow-up. Finally, the patients in whom hormonal
abnormalities or size mass variations developed at the last follow-
up were submitted to tests at least another twice, but revealed no
signs of hypersecretion or malignancy of the mass.
Clinical data in patients with adrenal mass enlargement
No difference in gender, lesion side or mass dimension
(categorized in tertiles), or in presence or absence of endocrine
abnormalities, obesity, diabetes and hypertension was recorded at
entry among the 32 patients who subsequently developed a mass
increase at follow-up. In addition, in these patients the appearance
of endocrine alterations over time (nine out of 32, 28%) was
similar to that observed in patients who showed a mass decrease
(eight out of 24, 33.3%) and in those who presented no variation in
mass dimension (18 out of 59, 30.5%).
DISCUSSION
The management of adrenal incidentalomas is becoming an
important aspect of health care, and its importance may increase
further because the extensive use and advances in imaging
technology could reveal an even higher incidence of adrenal
masses. While several concordant diagnostic and therapeutic
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Figure 2 Estimated overall cumulative risk of adrenal mass enlargement
(A) and mass reduction (B) over time in patients with adrenal
incidentalomas (n¼115).
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Figure 3 Estimated overall cumulative risk of developing endocrine
abnormalities in patients with adrenal incidentalomas (n¼115).
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salgorithms have been proposed for management of patients with
adrenal incidentalomas, follow-up studies are scanty and those
reported in the literature are not univocal, probably on account of
different duration of observation, number of patients studied and
methodological approaches adopted (Jockenhovel et al, 1992;
Barzon et al, 1999; Siren et al, 2000). Barzon et al (1999), in the
most comprehensive study to date, reported that though the risk of
malignancy was very low even in the case of an increment in mass
size, the large incidentalomas should be carefully followed-up due
to the elevated probability of hyperfunction which, in their study,
occurred in two out of 75 patients studied. Other authors have
similarly reported the development of overt hypersecretion of the
mass over time and even occasional malignant transformation of
adrenal incidentalomas (Hensen et al, 1990; Jockenhovel et al,
1992). In contrast, no shift toward malignancy or functional
hyperactivity was observed in several other studies (Osella et al,
1994; Barry et al, 1998; Terzolo et al, 1998; Rossi et al, 2000; Siren
et al, 2000; Grossrubatscher et al, 2001). Thus, the natural course
of adrenal incidentalomas still requires further clarification.
The novelty of the present investigation derives from several
important aspects. This is a prospective study investigating the
morpho-functional evolution of apparently benign and nonfunc-
tioning adrenal masses. The study was performed on a large
number of patients and the length of observation was sufficient to
evaluate the possible modifications of these tumors. Furthermore,
this follow-up was conducted in a single Unit with the same
physicians and technicians, so that potential bias deriving from
different diagnostic procedures or different laboratory methods
was avoided. In addition, the majority of the patients underwent
regular yearly tests and even patients who developed mass
morpho-functional variations over time were submitted to tests
for at least another 2 years.
Our first major finding is that, in agreement with several reports
(Reincke et al, 1992; Fernandez-Real et al, 1994; Osella et al, 1994;
Mantero et al, 1997; Barzon et al, 1998; Terzolo et al, 1998;
Mantero et al, 2000; Sworczak et al, 2001), patients with adrenal
incidentalomas frequently show isolated subtle subclinical endo-
crine alterations. Several terms have been adopted to define these
forms, on the basis of the hormone involved, such as pre-,
subclinical or silent Cushing’s syndrome, and preclinical hyper-
aldosteronism or pheochromocytoma, but the clinical significance
of these abnormalities remains unknown. In particular, we do not
know whether these subclinical syndromes may result in progres-
sion towards overt diseases. On the basis of our data this does not
seem to occur since in no case did confirmatory tests detect
patients with specific endocrine diseases. Furthermore, these
hormonal alterations normalized spontaneously over time in the
majority of cases, as similarly reported by other authors (Terzolo
et al, 1998). We also found that the risk of developing new
subclinical endocrine alterations remained constant over time
(even 6–7 years after the first observation) and was independent of
baseline morpho-functional characteristics of the masses, indicat-
ing that neither mass size nor other parameters were predictors of
these subclinical endocrine abnormalities.
The second major finding of our study concerns the morpho-
logical evolution of the mass over time. In the literature changes in
size have been reported in adrenal incidentalomas (Bastounis et al,
1997; Barry et al, 1998; Terzolo et al, 1998; Barzon et al, 1999; Siren
et al, 2000; Libe et al, 2002; Grumbach et al, 2003), with such
variations sometimes believed to reflect a more aggressive growth
rate (Mansmann et al, 2004). Barzon et al (1999) reported that
incidentalomas tend to undergo a period of increase in mass size
but thereafter remain unchanged, suggesting the possible existence
of a programmed end point of growth of adrenal masses. In
contrast, Grossrubatscher et al (2001) found that adrenal mass
enlargement may occur unpredictably at any time, sometimes after
a long period of ‘quiescence’. In the present study we noted
frequent increments but also reductions in mass size, although
such variations consistently proved to be small. In addition, the
risk of mass enlargement was constant over time and no basal
predictor was present either with regard to morphological
characteristics, such as initial mass dimensions, or functional
status, such as the presence of subclinical endocrine alterations at
entry. Finally, our data showed that mass enlargement was never
associated with the development of the endocrine alterations and
with malignant transformation of these lesions. Thus, mass
increase was casual and, in our opinion, should not be considered
a marker of hormonal hyperfunction or of malignancy.
The finding that evolution of the mass towards clinically
manifest or malignant forms was not observed in our study
implies that follow-ups may be carried out at fairly long intervals
of time. Therefore, a careful morpho-functional evaluation should
be undertaken above all at the first observation of the patients,
since if the mass proves to be benign and nonfunctioning this
picture will probably remain unchanged in the future as well.
However, the fact that size enlargement and subtle hormonal
alterations may occur at any time, even after a long period of
quiescence, does suggest that clinical surveillance should be
maintained for a prolonged period. For these reasons, in patients
with adrenal incidentalomas and no sign of hormonal hypersecre-
tion or malignancy at the first observation we propose a follow-up
involving a radiological (CT) examination every 2 years and an
hormonal evaluation every 3 years up to 7–10 years. If hormonal
and morphological parameters remain unchanged further follow-
ups can be avoided.
In conclusion, we found that patients with adrenal incidenta-
lomas frequently show subtle subclinical hormonal alterations not
corresponding to specific endocrine diseases. In addition, we
observed that mass increase and the development of new hormonal
abnormalities over time are not correlated, can appear at any time,
are not associated with any basal predictor and, finally, that are not
necessarily indicative of malignant transformation or progression
toward overt disease. Therefore, our data minimize the risk of
morbidity and mortality from hormone hypersecretion or
malignancy, at least for the period analyzed by our protocol, and
warn of the risk of overtesting and overtreating these patients.
Accordingly, a conservative approach of these masses appears
reasonable, and follow-ups conducted at long intervals over a
prolonged period of time seem to be the best choice for
management of patients with adrenal incidentalomas.
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